No Data
Shenzhen Salubris Pharmaceuticals' H1 revenue increased by 20%, but net profit growth is under pressure. The launch of two new drugs is facing regulatory negotiations.
① In the first half of this year, shenzhen salubris pharmaceuticals' revenue grew by more than 20%, but net profit attributable to shareholders only increased by less than 2%; ② During the reporting period, shenzhen salubris pharmaceuticals had two innovative products approved for listing, both of which have passed the initial review by the national discussion this year; ③ shenzhen salubris pharmaceuticals has four new drugs undergoing market approval, including three chemical drugs and one biological drug.
shanghai microport endovascular medtech(group)co.,ltd. net profit in the first half of the year increased by more than 44%. Can going overseas alleviate the impact of Castor price reduction?
①Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. accelerated its "going abroad" strategy, and its overseas revenue in the first half of the year increased by 67.04% year-on-year, accounting for 8.84% of the total revenue increase. ②A reporter from "Science and Technology Innovation Board Daily" asked personnel from Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. whether they would correspondingly reduce the selling price to dealers in response to the significant price reduction of the Castor bracket terminal. The other party refused to disclose more information, citing "inconvenience to reply".
High inventory combined with industry pressure, Chongqing Taiji Industry's H1 revenue and net profit both declined | Interpretations
In the first half of this year, Chongqing Taiji Industry's net profit was 0.495 billion yuan, a year-on-year decrease of 12.51%. The company stated that the poor performance in the first half of the year was mainly due to the high base of the same period last year and the high social inventory of some products.
Behind the "cliff-like" decline in performance of Beijing Wantai Biological: vaccine business revenue decreased by more than 80% | interpretations
①The main reason for the significant decline in the performance of beijing wantai biological pharmacy enterprise's H1 is the decrease in sales revenue of the bivalent HPV vaccine. ②The revenue of the company's diagnostic division exceeded the vaccine division, while overseas revenue saw a certain year-on-year growth. ③The production conditions for the commercialization of the nonavalent HPV vaccine of the company are in place, and the listing application is progressing according to plan.
How promising is the vitamins bull market? Zhejiang Nhu's Q2 net profit of 1.335 billion yuan reached a new high|Interpretation of financial report.
① Vitamins have significantly boosted manufacturers' performance in the bull market; ② Q2 net profit of Zhejiang Nhu reached a new high compared to the same period in history; ③ The company benefits from a high proportion of overseas business; ④ The Q3 increase has widened, further benefiting manufacturers.
The gross margin of injection products in the solution category has declined, and the imeik technology development's Q2 performance growth rate has dropped to single digits| Speed reading announcement.
①Imeik Technology Development's H1 revenue and net income growth rate slowed down. ②The gross margin of solution injection products has declined, and its proportion in total revenue has further decreased. ③In addition to laying out research and development pipelines for botulinum toxin, GLP-1 drugs, the company is also further expanding in the medical beauty equipment field.